BioNTech SE (BNTX)

247.68
-2.65(-1.06%)
After Hours
247.00
-0.68(-0.27%)
- Real-time Data
  • Volume:
    1,645,307
  • Bid/Ask:
    246.00/248.49
  • Day's Range:
    245.28 - 252.80

BNTX Overview

Prev. Close
250.33
Day's Range
245.28-252.8
Revenue
8.98B
Open
252.8
52 wk Range
75.47-462.56
EPS
18.95
Volume
1,645,307
Market Cap
60.46B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
4,371,844
P/E Ratio
13.21
Beta
-
1-Year Change
188.2%
Shares Outstanding
241,521,065
Next Earnings Date
Nov. 09, 2021
What is your sentiment on BioNTech SE?
or
Market is currently closed. Voting is open during market hours.

BioNTech SE News

BioNTech SE Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellSellSellBuy
Technical IndicatorsNeutralStrong SellSellStrong SellStrong Buy
SummarySellStrong SellSellStrong SellStrong Buy

BioNTech SE Company Profile

BioNTech SE Company Profile

Employees
2500

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Read More
  • Should be strong buy!
    0
    • Pfizer & BioNTech Got 'Full FDA Approval' For Its COVID Vaccine
      0
      • This is criminal!
        0
        • Wtf
          0
          • Analyst target $115
            0
            • Time to get back to 31 i guess
              2
              • whats better this one or pifzer
                0
                • When will this go up?
                  0
                  • Wow
                    0
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.